All lobbying filings

Broad Institute Inc.

Broad Institute Inc. filed a Q3 report for Broad Institute Inc. on October 20, 2026.

Lobbying for Broad Institute Inc. · Biomedical and Genomic Research

As filed: BROAD INSTITUTE INC. for BROAD INSTITUTE INC.

All filings by Broad Institute Inc. · Everything Broad Institute Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$60,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 8

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Budget/Appropriations

- General education about biomedical research and support for scientific funding. Transparency of federal funding for medical research dollars, including indirect costs. - Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Support for the NIH All of Us Program. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). - Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance. FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495).

Science/Technology

- General education about biomedical research and support for scientific funding. - Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. - Federal policies related to Office of Management and Budget (OMB) Uniform Guidance and their implications for federally funded biomedical research and research institutions. - Federal science and technology policy, including Office of Science and Technology Policy (OSTP) priorities related to the future of federally supported research, scientific institutions, and national research capabilities. - Federal policies and investments related to data infrastructure and artificial intelligence for biomedical research, including standards for secure and scalable data ecosystems.

Medical/Disease Research/Clinical Labs

- General education about biomedical research and support for scientific funding. - Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. - Education and awareness regarding genetic medicines for rare and ultra-rare diseases.

Defense

- Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance. FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495). - Education and discussion regarding Broad Institute capabilities and technologies relevant to national biological intelligence, biosurveillance, and reconnaissance (ISR). - General education regarding Broad Institutes research capabilities and areas of potential relevance to Defense Advanced Research Projects Agency (DARPA) programs and priorities.

Bills named in this filing 4

H.R. 9260
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
H.R. 8800
National Defense Authorization Act for Fiscal Year 2027
S. 4784
National Defense Authorization Act for Fiscal Year 2027
H.R. 9495
Department of Defense Appropriations Act, 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.